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The increased expression of gonadotropin releasing hormone receptor (GnRH-
R) in brain has been strongly linked to Alzheimer disease. Therefore, the devel-
opment of radiolabeled imaging agents for GnRH-R is relevant for early diag-
nosis of Alzheimer disease. We have recently disclosed the discovery of two
promising compounds displaying nanomolar-range affinity for the GnRH-R. In
the present study, a preclinical evaluation of the compound properties was per-
formed to evaluate their potential as single photon emission computed tomog-
raphy (SPECT) radiotracers for imaging the GnRH-receptor. The compounds
were assessed in vitro by performing serum stability analysis by human and rat
serum, metabolic profiling by human liver microsomes, and exploratory rat
brain autoradiography. The investigated compounds displayed satisfactory sta-
bility against human, rat serum, and liver microsomal metabolism, which
favors their potential as SPECT-imaging agents. Additionally, we identified
and quantified the formation rate of the metabolites by fragmentation of up to
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five mass spectrometric stages. The GnRH-R rat brain specificity of these com-
pounds was tested in competition with a known ligand for the receptor and the
in vitro autoradiography confirmed that compounds 3 and 4 binds to rat
GnRH-R in different rat brain regions.
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1 | INTRODUCTION
Novel radiotracers are needed to monitor, diagnose and
treat diseases, and to develop a deeper understanding of
human physiology and pathophysiology.1,2 Single photon
emission computed tomography (SPECT) is a widely used
medical imaging technique for diagnosis and monitoring
treatments. A SPECT-radionuclide emits a single photon
with each disintegration. The photon is further detected
by gamma cameras and processed by a computer to gen-
erate an image. We have selected to study SPECT as the
medical imaging technique due to its major advantages:
(a) The technique is less expensive and more convenient
compared with other molecular imaging techniques such
as positron emission tomography, (b) accessible gamma
cameras are available worldwide, and (c) the production
of SPECT-radiotracers is not limited to nearby
cyclotrons.3
Gonadotropin releasing hormone (GnRH) and
gonadotropin releasing hormone receptors (GnRH-R)
are involved in a wide range of biological processes
like reproductive functions, sex behavior, cognition,
and more important several diseases such as cancer
and neurodegeneration.4-9 The presence of GnRH-R in
the brain is especially interesting since the increase of
GnRH-R is strongly linked to Alzheimer disease.10-16
GnRH-R is mainly expressed in the hypothalamus-pitu-
itary-gonadal axis (HPG axis) together with GnRH
where it has its main function in reproductive physiol-
ogy. The GnRH, also known as luteinizing-hormone
releasing hormone (LHRH), is a neurohormone pro-
duced in the hypothalamus and released in a pulsatile
manner into the hypophysial portal bloodstream. When
it reaches the pituitary gland, it binds to its own G-
protein coupled receptor (GnRH-R) stimulating the
production of two gonadotropic hormones in the ante-
rior pituitary gland—luteinizing hormone and follicle
stimulation hormone. Furthermore, the release of
gonadotropins acts in the gonads to produce androgens
and estrogens. The release of gonadotropins is
controlled by the pulsatile release of GnRH in the
hypophysial portal blood stream and by the feedback
mechanism of androgens and estrogens.17 Much is yet
unknown of the GnRH and GnRH-R involvement
in Alzheimer disease. However, dysfunction of the
HPG-axis and the feedback mechanism have been
shown to be implicated in Alzheimer disease
pathophysiology.10-16
We have recently revealed the discovery of GnRH-R
antagonist candidates based on a benzimidazole-pipera-
zine molecular scaffold suitable for SPECT imaging, com-
pounds 1 and 2, Figure 1.18,19 Further diversification
FIGURE 1 Previously disclosed compounds. Compounds 1 and 2 from the initial study.18 Compounds 3 and 4 were developed in the
continuation of the initial study. 20
2 FJELLAKSEL ET AL.
from the initial study led to the discovery of two highly
promising 123I-labelled triazole-benzimidazole GnRH-R
antagonists, compounds 3 and 4, Figure 1.20
In early stage drug development, determination of
serum and metabolic stability are essential prior to in
vivo evaluation.21,22 This early stage stability evaluation
is especially important in the development of radio-
iodinated tracers as the rate of metabolism and any possi-
ble deiodination process will affect their possible
application as a SPECT radiotracer. Furthermore, meta-
bolic profiling is an accurate modeling of metabolic phase
I activity enabling us to estimate the metabolism rate and
the metabolic deiodination rate which predicts the ability
for the drugs as SPECT radiotracers. Therefore, further in
vitro evaluation of compounds 3 and 4 to develop a
SPECT radiotracer targeting the GnRH-R was performed.
Phase I metabolism has also been reported for similar
GnRH-R antagonist possessing the same benzimidazole-
piperazine scaffold.23 However, for the radioiodinated
analogues included in the present study, a deeper under-
standing of the rate of metabolism and deiodination was
pursued. In the present study serum stability, metabolic
profiling from human and rat liver microsomes and rat
brain GnRH-R specificity was evaluated by in vitro auto-




Acetonitrile and trifluoroacetic acid were obtained from
Sigma Aldrich (St. Louis, Missouri). Silica gel 60 TLC
plates with fluorescence indicator (F254) from Merck
(Darmstadt, Germany) were used. Anhydrous conditions
were conducted only if mentioned. Rat serum and
human serum were a kind gift from the Vascular Biology
research group at UiT—The Arctic university of Norway.
Rat and human liver microsomes were purchased from
Thermo Fisher Scientific (Waltham, Missouri) MilliQ
water rinsing system from Millipore was used. β-nicotin-
amide adenine dinucleotide phosphate sodium salt
(NADP), β-nicotinamide adenine dinucleotide phosphate
reduced tetrasodium salt (NADPH), D-glucose-6-phos-
phate, and D-glucose-6-phosphate dehydrogenase were
also purchased from Sigma Aldrich. 125I-labelled [D-
Trp6]-LHRH was bought from Perkin-Elmer (Norway).
Compounds 3 and 4 which were used unlabelled in this
study have previously been radiolabelled, and the radio-
labelling is described in a previous publication.20 The
synthesis of compounds 3 and 4 are described in section
2.2.
2.1.1 | Animals
Male Wistar Han IGS rats of 6 to 9 weeks of age were
purchased from Charles River (Germany). The animals
were housed in the Department of Comparative Medicine
at UiT—The Artic University of Norway. The animals
had access to water and standard chow from Scanbur, BK
(Norway) ad libitum. All experimental protocols were
approved by The Norwegian Food Safety Authority and
conducted in accordance to the Norwegian law, FOR-
2017-04-05-451 (Project Fots id: 8353).
2.2 | Synthesis of compounds 3and 4
The key intermediate and compounds 3 and 4 were syn-
thesized according to previous published procedures and
details are attached in the supporting information,
Scheme 1.20
SCHEME 1 Synthetic route for
the syntehsis of compounds 3 and 4





200 mg (1 Eq, 0.5 mmol) of 2-(4-(tert-butyl)phenyl)-4-(4-
(prop-2-yn-1-yl)piperazin-1-yl)-1H-benzo[d]imidazole (3)
was added to a solution of 1.7 mL (28 mg/mL) solution of
2-fluoroethyl azide (0.5 mmol, 1 Eq), 76 μL of
triethylamine (0.5 mmol, 1 Eq), 100 mg Cu (II)iodide (0.5
mmol, 1 Eq), 135 mg N-Iodosuccimide (0.6 mmol, 1.1 Eq)
in 10 mL DMF. The reaction mixture heated and stirred
by microwave for 3 hours, 100oC. The solvents were evap-
orated and the compound purified by HPLC. Method: 25
mL/min. initial 95% H2O 0.1% TFA, 5% ACN 0.1% TFA.
At 15 minutes linear change to 5% H2O 0.1% TFA, 95%
ACN 0.1% TFA. The product gave a rf 7.19 minutes, was
lyophilized, and gave a white powder. (13 mg, 4% yield).
Purity: 95.7 % 1H-NMR (400 MHz, Methanol-d4), δ in
ppm = 8.30(s, 1H), 8.10 (d, J = 8.2 Hz, 2H), 7.64 (d, J =
8.4 Hz, 3H), 6.74 (d, J = 8.3 Hz, 1H), 4.81(s, 2H), 4.64(s,
2H), 3.66 (Br s, 8H), 1.41(s, 9H) 13C NMR (101 MHz,
Methanol-d4) δ in ppm = 156.2, 141.4, 137.6, 134.8, 129.0,
128.7, 127.1, 113.9, 83.6 (1JCF = 170 Hz), 81.9 (1JCF = 170
Hz), 52.8, 52.2 (2JCF = 20 Hz), 52.0 (2JCF = 20 Hz), 51.7,
35.9, 31.6 IR (neat): 2966, 1664, 1460, 1182, 1132 HRMS





200 mg (1 Eq, 0.5 mmol) of 2-(4-(tert-butyl)phenyl)-4-
(4-(prop-2-yn-1-yl)piperazin-1-yl)-1H-benzo[d]imidazole
(3) was added to a solution of 1.7 mL (28 mg/mL)
solution of 2-fluoroethyl azide (0.5 mmol, 1 Eq), 76 μL
of triethylamine (0.5 mmol, 1 Eq), 100 mg Cu (II)
iodide (0.5 mmol, 1 Eq), 135 mg N-Iodosuccimide (0.6
mmol, 1.1 Eq) in 10 mL DMF. The reaction mixture
heated and stirred by microwave for 3 hours, 100oC.
The solvents were then evaporated and purified by
HPLC. Method: 25 mL/min. initial 95% H2O 0.1%
TFA, 5% ACN 0.1% TFA. At 15 minutes linear change
to 5% H2O 0.1% TFA, 95% ACN 0.1% TFA. The prod-
uct gave a rf 7.19 minutes, was lyophilized, and gave a
white powder (19 mg, 6% yield). Purity = 95.9% 1H-
NMR (400 MHz, methanol-d4), δ in ppm = 8.08 (d, J
= 8.1 Hz, 2H), 7.72 (d, J = 7.6 Hz, 2H), 7.46 (d, J =
4.9 Hz, 2H), 7.13(s, 1H), 4.59(s, 2H), 3.72(Br s, 8H),
1.39(s, 9H) 13C NMR (101 MHz, Methanol-d4) δ in
ppm = 157.5, 151.9, 142.7, 140.9, 136.0, 131.3, 128.8,
127.6, 127.0, 124.1, 114.1, 109.7, 89.0, 83.4(1JCF = 171
Hz), 81.7(1JCF = 171 Hz), 53.1, 52.7(2JCF = 20 Hz),
52.5(2JCF = 20 Hz), 52.3, 36.1, 31.5 IR (neat): 2965,
1663, 1437, 1179, 1126 HRMS ESI m/z: Found
588.1743 [M+H]+ Calculated 588.1748.
2.3 | Evaluation of compounds 3 and 4 in
human and rat serum
The stability of compounds 3 and 4 was investigated in
human and rat serum. In assay, compounds 3 and 4 were
dissolved in a mixture of ethanol/polysorbate 80/water
for injection (5:5:90). The compounds were then incu-
bated with 400 μL human and 300 μL rat serum, to give a
final concentration of 5mM and 6.5mM at 37oC, respec-
tively. An aliquot (40-50 μl) was subsequently extracted
with ice-cold acetonitrile at 0, 10, 30, 60, 120, 240, and
1320 minutes post-incubation. Samples were centrifuged
at 13000g for 5 minutes. The supernatants were collected
and analyzed by LTQ Orbitrap XL with electrospray ion
source (ION-MAX) and thermo scientific Accela auto-
sampler with Thermo Hypersil Gold 50 × 2.1 mm, 1.9 um
C18 reverse phase column. The detection window was
constrained to m/z 400 to 620 and the percentage
remaining compound left in the samples were analyzed.
Instrument characteristics and program parameters for
serum stability analysis are provided in the Supporting
Information.
2.4 | Incubation with rat and human
liver microsomes
In brief, stock solutions (2mM) of the substrates were
prepared by dissolving compounds 3 and 4 in acetonitrile:
water (v/v, 75:25). The compounds were incubated in a
total volume of 1 mL in Pyrex test tubes at 37oC in a
shaking water bath (Heto-Holten, Allerod, Denmark)
with rat and human liver microsomes. Human liver
microsomes consisted on a mixed gender pool of 15
donors (20 mg/mL protein), whereas rat liver microsomes
consisted of an undetermined number of male donors at
20 mg/mL protein. The incubation was performed in
NADPH regeneration system in HEPES buffer (pH 7.4)
containing 19.4mM glucose-6-phosphate, 0.91mM
NADPH, 0.84mM NADP, and 5.72 units of glucose-6-
phosphate dehydrogenase.24 At 0, 2, 5, 15, 30, 60, 120,
and 180 minutes, 0.1 mL aliquots were taken and trans-
ferred to Eppendorf tubes containing 0.1 mL ice-cold ace-
tonitrile and 100 ng/mL internal standard to quench the
reaction. The samples were centrifuged at 21000g in a
5424R Eppendorf centrifuge (VWR, Oslo, Norway). The
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supernatants were then collected and transferred to
HPLC insert-vials for further analysis on the LC-MS sys-
tem. Positive and negative controls were included in each
incubation mixture in order to validate the experimental
setup. As a positive control, lidocaine was used, the
metabolism of lidocaine is shown in Figure S3. Lidocaine
has a well-known metabolic profile and, in addition,
structural similarities with the substrates to be studied in
the present study.25,26 As negative control, a mixture con-
taining all the components of the experiments except the
substrates and an incubation containing the substrates
without the microsomes was included.
2.5 | Semi-quantitative analysis of
compounds 3and 4 and screening for
metabolites
The assumption of similar response for the metabolites as
for the parents is unrealistic, and the concentrations
should therefore clearly be regarded as semi-quantitative.
However, the relative concentrations of each metabolite
over time illustrate the metabolization in a representative
manner. 2-(4-(tert-butylphenyl)-4-(4-(2-fluoroethyl)piper-
azin-1-yl)-1H-benzo[d]imidazole was used as an internal
standard at a concentration of 100 μg/mL. Calibration
curves were constructed for the parent compounds (3 and
4) in a concentration range from 0.5 to 8 μg/mL. Calibra-
tion standards were made in matrix and showed appro-
priate linearity in the range of the concentrations
studied, experiments were performed at least three times,
with at least three injections each time. The linearity for
compound 3 was found to be R2 = 0.9731, y = 0.1929x +
0.1354, for compound 4 R2 = 0.9608, y = 0.2072x +
0.1426.
2.6 | HPLC-MS/MS
The rate of metabolism and metabolite identification was
performed on a Waters (Millford, Massachusetts) Xevo
G2 Q-ToF mass spectrometer connected to a Waters
Acquity UPLC I-class separation module. The separation
was achieved on a Waters Acquity BEH C18 2.1 × 100
mm column with 1.7 μm particle size. The mobile phases
consisted of A: water with 0.1% formic acid and B: aceto-
nitrile with 0.1% formic acid. The analysis was performed
with gradient elution starting with 2% B with a linear
increase to 95% B after 10 minutes. The flow rate was set
to 0.6 mL/min, the injection volume was 5 μL, and the
column temperature was set to 65C. For full scan analy-
sis of all compounds, the mass spectrometer had a capil-
lary voltage of 600 V, the cone voltage was set to 30 V,
the cone gas flow was set to 10 L/h and 130C, and the
desolvation gas flow was set to 800 L/h and 450C. Nitro-
gen from a Genius NM32LA nitrogen generator (Peak
Scientific, Incinnan, Great Britain) was used as both cone
and desolvation gas. The mass range was set to m/z 105
to m/z 1200, and the analysis was performed with posi-
tive electrospray ionization. Leucine-enkephaline with an
m/z of 556.2771 was used as lockspray for increased mass
accuracy. For MS/MS experiments, similar settings were
used but instead of full scan analysis the protonated
molecular ion of each compound was set as precursor ion
for fragmentation. The fragmentation was done by colli-
sion induced fragmentation with argon (Aga, Oslo, Nor-
way) as collision gas, and a collision energy ramp of 20 to
40 eV was used for all compounds. Fragments were
detected in the mass range m/z 50 to m/z 650. Identifica-
tion of metabolites was done manually by considering
normal phase 1 metabolism and by the software Met-
abolynx by Waters set to identification of phase 1
metabolites.
2.7 | HPLC-MS/MS for characterization
of metabolites
To obtain as much structural information about the
metabolites as possible a Thermo Scientific LTQ Orbitrap
XL with electrospray ion source (ION-MAX) was used
with fragmentation up to MS5. Additional fragmentation
spectra and program parameters are given in the
supporting information. The interpretation of MSn spec-
tra is not confirmed by isotopic labelling of the com-
pounds and is based on theoretical fragmentation
patterns from the software Metabolynx which is part of
the Waters Masslynx software, as well as experiential
knowledge. This means there might be an uncertainty in
some of the structures with regard to the position of func-
tional groups, etc.
2.8 | Preliminary rat brain
autoradiography studies
Rats were anesthetized using isoflurane (Induction 4%,
maintenance 2% in oxygen) and euthanized while still
under anesthesia with an overdose of pentobarbital (100
mL/kg) administered intraperitoneally. Brains were rap-
idly removed, embedded in O.C.T. Tissuetek (Sakura-
Finetek, USA) and frozen by immersion in isopentane
and liquid nitrogen. Coronal brain sections (−20C, 20
μm thickness) were prepared on a cryostat and
mounted on Superfrost Plus glass slides (Carl Roth
GmbH & Co KG, Karlsruhe, Germany). Sections were
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allowed to thaw and dry at room temperature for 30
minutes. Samples were pre-incubated with TMSA buffer
(25mM Tris, 5mM MgCl2, 32mM sucrose, 1% BSA, pH
7.4) for 30 minutes. Thereafter, incubation with com-
pounds 3 and 4 in different concentrations, ranging
from 0 to 100mM for 60minutes, was performed at
room temperature in TMSA buffer. Slides were washed
with TMSA buffer for 5 minutes and incubated for 60
minutes at room temperature with 125I-labelled [D-
Trp6]-LHRH (0.1 nM). The sections were then washed
four times with ice cold TA buffer (25mM Tris, 1% BSA
pH 7.4) and once in milliQ water for 5 minutes. The
samples were dried, exposed to a phosphor imaging
screen (FUJI BAS-MS 2340 GE Healthcare Lifescience)
for 7 days at −20oC, and scanned with Fujifilm bio-
imaging analyser BAS-5000. Images were processed by
Image J software (NIH). For the morphological studies,
the slides were kept at −80 and later labelled with fresh
SignalStain DAB Substrate (CST #8059) taking advan-
tage of the intrinsic peroxidase catalytic activity of the
tissue. Rat brain histological pictures were taken with a
VS120 Virtual Slide Microscope (Olympus) with a x20
magnification.
3 | RESULT AND DISCUSSION
Compounds 3 and 4 were synthesized in a seven-step
synthesis as shown in the experimental section with a
non-optimized yield of 4% for 3 and 6% for 4, Scheme 1.
Serum stability of compounds 3 and 4 was studied by LC-
MS, and results are shown in Table 1. The compounds
were found to be stable in vitro in both human and rat
serum. A minimum of 81% of the compounds remained
after 120 minutes incubation. After 22 hours, more than
70% of the compounds remained, indicating good stabil-
ity in human and rat serum.
The next step in the radiotracer development of com-
pounds 3 and 4 required metabolic profiling to investi-
gate their stability for phase 1 metabolism. MS/MS
fragment ions of compounds 3 and 4 were identified by
LC-MS/MS and are shown in Figure 2. The identity of
TABLE 1 Serum stability of compounds 3 and 4 in human and rat serum
Minutes
Compound 3 Compound 4 Compound 3 Compound 4
Human seruma Human seruma Rat seruma Rat seruma
0 100 100 100 100
30 97 109 101 98
60 107 99 94 92
120 103 106 98 81
1320 84 91 86 70
aStability given as the mean of two experiments.
FIGURE 2 Structural information
obtained by LC-MS/MS. MS/MS
spectrum of compound 3 to the left and
compound 4 to the right. Major product
ions are shown in the structures as mass
to charge ratio (m/z)
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the produced metabolites was achieved based on the
comparison of fragmentations for the metabolites and the
parent compounds, and the structures were partly deter-
mined. MSn spectra with structural information of metab-
olites can be found in Figures S4 to S39. An overview of
molecular ions and main fragment ions of the metabo-
lites are given in Tables 2 and 3.
Major fragment ions for compound 3 were identified
as m/z 560, 497, 473, 418, 333, and 292. The fragment ion
m/z 560 is due to a loss of two nitrogen atoms, from the
triazole-ring. The m/z 497 fragment is due to a fragmen-
tation of the triazole-ring where the fluoroethyl group in
addition is lost, while the fragment m/z 473 is due to the
loss of the entire triazole-ring including the fluoroethyl
group. Signal m/z 418 is due to a fragmentation of the
piperazine ring.
The metabolites from compound 3 were identified as
M1 m/z 604 (hydroxylation), M2 m/z 578 (hydration and
two demethylations), M3 m/z 584 (two sequential
desaturations), M4 m/z 461 (loss of the fluoroethyl-
group), and M5 m/z 477 (hydroxylation and loss of the
fluoroethyl-group) as shown in Table 2.
M1 (m/z 604) shows a typical difference of 16 amu
compared to compound 3 at m/z 588, which is due to a
hydroxylation product. The MS/MS spectrum shows a
fragment ion at m/z 576, equal to fragment m/z 560 of
compound 3. The signal at m/z 489 and m/z 434 is equal
to the signal at m/z 473 and m/z 418 of compound 3. M2
(m/z 578) is 10 amu lower than for compound 3 at m/z
588, due to hydration and two demethylations. The frag-
ment ions at m/z 461 and m/z and 434 are equal to m/z
473 and m/z 418 for compound 3. The signal m/z 307 is
equal to m/z 418 for compound 3 but with an additional
loss of iodine on the benzimidazole. The signal at m/z
295 is equal to the fragment m/z 418 for compound 3,
however due to the additional loss iodine and 12 amu,
which reflects the loss of a carbon nearby the nitrogen in
the piperazine ring. Identification of the metabolites M3,
M4, and M5 was performed by LC-MS and MS/MS analy-
sis of the parent and fragment ions and additionally by
the Metabolynx toolbox from MassLynx software
(Waters).
There is a remarkable similarity between metabolism
by rat and human liver microsomes for compound 3, as
shown in Figure 3. Notably, compound 3 is metabolized
at a slightly slower rate in human liver microsomes com-
pared with rat liver microsomes. The maximum amount
of M1 is produced within 15 to 30 minutes. In addition,
M1 and M2 are produced at a lower rate in human than
in rat liver microsomes. Additionally, the half-life of com-
pound 3 incubated in human liver microsomes was found
to be 43 minutes and for rat liver microsomes 47 minutes.
TABLE 2 Compound 3 incubated with human liver microsomes
Identity Retention Time, minutes [M+H]+ Metabolite Description Major Fragment Ions (m/z)
3 4.01 588 Parent 560, 497, 473, 418,
M1 3.05 604 3 [+OH] 576, 489, 434
M2 2.91 578 3 [+H2O, −CH3, −CH3] 461, 434, 307, 295
M3 3.82 584 3 [two sequential desaturations] a
M4 3.79 461 3 [−C5H6N3F] a
M5 2.82 477 3 [+OH−C5H6N3F] a
Note. Structural information obtained by LC-MS and LC-MS/MS of metabolites. Bold values represent diagnostic fragment ions.
aUnable to obtain reliable MS/MS data due to very low ion signals.
TABLE 3 Compound 4 incubated with human liver microsomes
Identity Retention Time, minutes [M+H]+ Metabolite Description Major Fragment Ions (m/z)a
4 3.17 588 Parent 560, 347, 292, 226, 180
M1 2.26 604 4 [+OH] 363, 308, 226, 180
M2 1.98 478 4 [+OH-I+H] 363, 308,
M3 2.52 335 4 [-C5H5N3FI] 292, 277, 262,
M4 2.16 558 4 [+OH-C2H3F] 402, 351, 308, 277
M5 2.08 578 4 [+H2O-CH2-CH2] 337, 308, 226, 180
M6 3.07 542 4 [-C2H3F] 386, 335, 292, 278, 266
aNote. Structural information obtained by LC-MS and LC-MS/MS of metabolites in human microsomes. Bold values represent diagnostic fragment ions.
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The metabolites M3 to M5 were produced in minor
amounts (Figure 3).
The ion chromatograms for compound 3 and the
metabolites M1 to M5 are shown in Figure S1, where the
increase of the metabolites is seen at the selected time
points 15 and 180 minutes for compound 3.
For compound 4, the fragmentation by LC-MS/MS
revealed the major fragment ions as m/z 560, 347, 292,
226, and 180. Similarly as for compound 3, the loss of two
nitrogen atoms is due to the fragment signal of m/z 560
from compound 4. The m/z 347 fragment ion is due to a
loss of triazole with the fluoroethyl group in addition to
the loss of iodine. The signal m/z 292 is due to a cleavage
of the piperazine ring. The m/z of 226 and m/z 180 are
due to a fragmentation in the triazole, where the signal at
m/z 226 indicates that the fluoroethyl group is still
present.
The metabolites from compound 4 were identified as
M1 m/z 604 (hydroxylation), M2 m/z 478 (hydroxylation
and deiodination), M3 m/z 335 (loss of the triazole with
the fluoroethyl group and iodine), M4 m/z 558 (hydrox-
ylation and loss of the fluoroethyl group), M5 m/z 578
(hydration and demethylation), see Table 3. M1 (m/z
604) shows a difference of 16 amu compared with com-
pound 4, which is due to a hydroxylation product. Fur-
thermore, fragment ions of M1 (m/z 604) corresponds to
a large degree on the fragments of compound 4 (frag-
ment m/z 363 corresponds to m/z 347, fragment m/z
308 corresponds to m/z 292, fragment m/z 226 corre-
sponds to m/z 226, and fragment m/z 180 corresponds
to m/z 180). M2 (m/z 478) is due to a hydroxylation in
addition to a deiodination. The fragment ions of M2 cor-
responds to a large degree on the fragments of com-
pound 4 (fragment m/z 363 corresponds to m/z 347,
fragment m/z 308 corresponds to m/z 292). In addition,
signals m/z 226 and m/z 180 are missing, which makes
iodine on the triazole important for the fragmentation,
and when the iodine is missing, these fragments are also
missing. M3 (m/z 335) is due to the loss of the triazole
with the fluoroethyl group and the iodine. The fragment
ions for M3 also correspond to a large degree to the
fragments for compound 4 (fragment m/z 292 corre-
sponds to m/z 292, fragment m/z 277, and m/z 262 cor-
responds to m/z 292). Fragment ion m/z 292 is due to
the loss of one CH2-group and subsequently another
CH2-group. In addition, the signals m/z 226 and m/z
180 are missing here as well, again indicating the
importance of the iodine on the triazole for the frag-
mentation. M4 (m/z 558) is due to a hydroxylation with
the loss of the fluoroethyl group at the triazole. Addi-
tionally, the fragment ions for M4 (m/z 558) corresponds
to a large degree on the fragments for compound 4
(Fragment m/z 402 corresponds to m/z 560 for com-
pound 4 with the additional loss of iodine, fragment m/
z 351 corresponds to m/z 347, however with the addi-
tional loss of a carbon, m/z 308 corresponds to m/z 292,
fragment m/z 277 corresponds to m/z 292, due to the
loss of one CH2-group). The signal for M5 (m/z 578) is
due to a hydration and two demethylations. As for the
other metabolites the fragment ions for M5 (m/z 578)
corresponds to a large degree to the fragment ions for
compound 4 (signal m/z 337 corresponds m/z 347, m/z
308 corresponds to m/z 292, m/z 226 corresponds to m/z
226, and m/z 180 corresponds to m/z 180). M6 (m/z
542) is due to a fragmentation of the fluoroethyl group.
The fragment ions for this metabolite also correspond to
a large degree to the fragment ions for compound 4
(The m/z 386 is due to the loss of iodine and two nitro-
gen atoms). The m/z 335 corresponds to m/z 347 with
the additional loss of a carbon, signal m/z 292 corre-
sponds to m/z 292. The m/z 278 and m/z 266 corre-
sponds to m/z 292 (difference of 12 amu) is due to a
FIGURE 3 Metabolic transformation of compound 3 with
metabolites. Upper graph presents the compound incubated with
human liver microsomes and the lower graph with rat liver
microsomes. The experiment was performed as two independent
experiments with four injections on LC MS-MS
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fragmentation on the piperazine where only a nitrogen
is left for m/z 266).
As with compound 3, the metabolism of compound 4
is similar in human and rat liver microsomes. However,
in the case of compound 4, the metabolism in rat liver
microsomes appears to be slightly slower than in human
liver microsomes, Figure 4. The main found metabolites
are M1, M2, and M4. More M1 are formed as compared
to M2 and M4 in human and rat liver microsomes. The
minor metabolites were M3, M5, and M6. Additionally,
the half-life for compound 4 incubated in human liver
microsomes was found to be 64 minutes and for rat liver
microsomes 86 minutes.
The ion chromatograms for compound 4 and the
metabolites M1-M6 are shown in Figure S2, where the
time-dependent increase in the metabolite levels are also
shown at the selected time points 15 and 180 minutes,
respectively.
Structural studies were performed in some of the
major metabolites. To identify the most probable position
for the hydration of metabolite M2 (compound 3) and the
hydroxylation on the metabolite M1 (compound 3) and
the metabolites M1, M2, and M4 (compound 4), further
MSn experiments were performed. Metabolite M2 for
compound 3 show two demethylations with a sequential
hydration. The most probable place such a demethylation
will occur is at the tert-butyl group. Fragmentation of M2
(compound 3) by MS2 to MS5 where performed and sev-
eral fragment ions were identified, Figure 5 (MS2). Addi-
tionally, fragment ions for compound 3 where analyzed
by MS2 to MS5 and compared with M1 (MS2 and MS3)
and M2 (additional spectra in the Supporting
Information).
Furthermore, compound 4 was analyzed by MS2 to
MS5 for fragmentation patterns. Metabolite M2 was frag-
mented to MS5 to identify the fragment ion for M2 from
compound 4. The fragment ions m/z 132.2 and 116.2
indicate that the hydroxylation occurred at the benzene-
ring on the benzimidazole group in Figure 6. For the
metabolites M1 (MS2 to MS5) and M4 (MS2 and MS3), the
same fragmentation patterns are seen as for M2 (com-
pound 4) for MS2 to MS5 which indicates that the hydrox-
ylation occur at the same position for these metabolites.
Additionally, the same fragmentation pattern was
observed for metabolite M1 (compound 3) in MS2 and
MS3 spectra as for metabolites M1, M2, and M4 (com-
pound 4) indicating the hydroxylation occurs at the ben-
zene-ring on the benzimidazole.
The metabolic profile identified five metabolites for
compound 3 and six metabolites for compound 4. In
light of the serum stability analysis and the metabolic
profiles, the metabolism of compounds 3 and 4 both in
rat- and human-liver microsomes is acceptable for an
imaging agent in human and rat. The metabolic half-
life was found to be 43 minutes (human liver micro-
somes) and 47 minutes (rat liver microsomes) for com-
pound 3. The half-life for compound 4 incubated in
human liver microsomes was found to be 64 minutes
and for rat liver microsomes 86 minutes. Even though
the half-life for compound 4 is relatively longer than
compound 3. The half-lives indicate that compounds 3
and 4 may be suitable as SPECT-imaging agents. The
metabolic profile for both compounds 3 and 4 are suit-
able for imaging agents and the rates of metabolism
and deiodination make them highly interesting for fur-
ther evaluation.
The serum stability analysis, metabolic profiling,
binding potential, and the lipophilicities according to
PSA and CLogP (Figure 1) lead us to further examine
compounds 3 and 4 as possible brain SPECT radiotracers.
For preliminary evaluation, the binding potential of these
compounds to rat brain GnRH-R was assessed by in vitro
rat brain autoradiography. Compounds 3 and 4 were
FIGURE 4 Metabolic transformation of compound 4 with
metabolites. Upper graph presents the compound incubated with
human liver microsomes and the lower graph with rat liver
microsomes. The experiment was performed as two independent
experiments with four injections on LC MS-MS
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incubated in a competitive binding against the GnRH-R
agonist [125I]-[D-Trp6]-LHRH.
The identifications of the different brain areas
whereas the competition for the receptor can be observed
were achieved by the observation and subsequent com-
parison of the in vitro autoradiography data, DAB stained
histological sections and the Rat Brain Atlas 4.027 (Fig-
ure 7). The decrease in the signal shows that compounds
3 and 4 specifically displace the radiolabeled GnRH ago-
nist [125I]-[D-Trp6]-LHRH. Compound 3 shows high
binding in areas of the corpus callosum, striatum, and
specially the optic nerve area. For compound 4, autora-
diographic data shows intense binding in areas of the hip-
pocampal formation, cortex, and the midbrain regions.
In a previous study by Jennes et al,28 most pro-
nounced uptake of a GnRH agonist in the rat brain was
observed in the hippocampal formation. In line with
these observations, our data for compound 4 (Figure 7)
show high specific binding in the hippocampal areas.
Additionally, and also matching the observations of
Jennes et al, higher uptake was observed in the sub-
iculum and the midbrain regions. Furthermore, Skinner
FIGURE 5 MS2 spectra for fragment ions for the metabolite M2 (compound 3) which most likely identifies M2 which occurs by two
demethylation with a sequential hydration
FIGURE 6 MS5 spectra to identify the fragment ions for
hydroxylation on metabolite M2 for compound 4
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et al,9 identifies GnRH effects and GnRH receptors out-
side the hypothalamo-pituitary-gonadal axis. Our results
for compound 3 are in accordance with the described
areas in Skinner publication showing high specific
uptake in cortex and striatum (Figure 7). Additionally,
immunohistochemistry (IHC) experiments were per-
formed using GnRH antibody. However, in our attempts
to identify the GnRH receptors by immunohistochemis-
try, after the AR protocol, no co-localization between pri-
mary antibody and 125I-labelled [D-Trp6]-LHRH was
found. The results are not conclusive since multiple fac-
tors are known to affect IHC protocols, most curious is
that our IHC pictures corresponds to those shown by
Jennes et al.28
Compound 4 showed a stronger reduction of the
[125I] [D-Trp6]-LHRH binding to GnRH-R compared
with compound 3. At a displacing concentration of 10μM,
compound 4 is able to almost completely inhibit the
binding of [125I] [D-Trp6]-LHRH with an Ki 0.3 nM29 for
GnRH-R in the rat brain. This is in consistency with our
previous findings showing that the inhibition potency of
compound 4 (Ki of 12.9 nM) was six-fold higher that of
compound 3 (Ki of 82 nM).
20
4 | CONCLUSIONS
Compounds 3 and 4 were evaluated in vitro to deter-
mine crucial properties concerning to their suitabilities
as GnRH-R molecular imaging agents. More than 70 %
of the compounds remained in rat- and human- serum
for 22 hours, which indicates that the compounds were
quite stable in rat and human serum. A thorough anal-
ysis of the phase 1 metabolism for compounds 3 and 4
revealed a metabolic half-life suitable for the possible
application of these compounds as SPECT imaging
agents. Five metabolites were identified and semi-quan-
tified for compound 3 and six metabolites were identi-
fied and semi-quantified for compound 4. Additionally,
in vitro autoradiography confirmed the binding poten-
tial of compounds 3 and 4 to rat GnRH-R in different
rat brain regions in competition to the agonist [125I] [D-
Trp6]-LHRH. In conclusion, a more suitable metabolic
profile and affinity for the GnRH receptor favorizes
compound 4 as the most promising SPECT radiotracer.
Further, in vivo characterization of these promising
compounds as GnRH-R SPECT radiotracers will be
explored.
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